| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Heron Therapeutics, Inc. /de/ (HRTX) has 11 insiders with recent SEC Form 4 filings, including 6 buys and 14 sells. HRTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 30.05M | $27.47M | - | |
| CEO | 662.1K | $605.4K | - | |
| CFO | 215.9K | $197.4K | - | |
| COO | 188.3K | $172.2K | - | |
| Dir | 123.7K | $113.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 24, 2017 | Manhard Kimberly80 | Executive VP, Drug Development | Sale+OE | 21,542 | $15.33 | $330,262.56 | -100% | |
| Jan 19, 2017 | Poyhonen John | Director | Buy | 10,000 | $12.20 | $122,000.00 | New | |
| Jan 19, 2017 | Tang Kevin C86 | Director, 10% Owner | Buy | 2,459,016 | $12.20 | $29,999,995.20 | +41.9% | |
| Aug 10, 2016 | Rosen Robert | President &CCO | Sale+OE | 100,000 | $23.30 | $2,329,894.64 | -85.0% | |
| Apr 21, 2016 | Rosen Robert | President | Sale+OE | 200,000 | $23.23 | $4,646,422.53 | -53.2% | |
| Jun 10, 2015 | Tang Kevin C86 | Director, 10% Owner | Buy | 121,212 | $24.75 | $2,999,997.00 | +2.6% | |
| Jun 2, 2015 | Manhard Kimberly80 | Director | Sale+OE | 13,208 | $23.09 | $304,918.36 | -100% | |
| Jun 2, 2015 | Tang Kevin C86 | Director, 10% Owner | Buy | 150,000 | $20.62 | $3,092,285.12 | +1.1% | |
| Mar 5, 2015 | Marshall Paul | SVP, Technical Operations | Sale+OE | 70,000 | $14.69 | $1,028,000.00 | -77.8% | |
| Mar 2, 2015 | Quart Barry D61 | Chief Executive Officer | Sell | 10,000 | $13.07 | $130,727.00 | -18.9% |